PATENT CLAIM ANALYSIS

Application Number: 16095607
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "013700"]

Abstract:
A method and pharmceutical compositon for the treatment of thrombotic thrombocytopenic purpura. The method and pharmceutical compositon uses a therapuetically effective amount of an antiplatelet thrombolysin comprising two polypeptide chains, an alpha chain and a beta chain. The antiplatelet thrombolysin of the invention can limit platelet adhesion and aggregation, restore platelets, red blood cell and hemoglobin levels, at the same time, reduce the level of lactate dehydrogenase, and effectively inhibits thrombocytopenia and schistocyte hemolytic anemia, so as to achieve the purpose of the treatment of TTP, which has a good prospect of clinical use.

Claim (Index 11):
The method of treating a mammal suffering from thrombotic thrombocytopenic purpura according to  claim 9 , wherein said antiplatelet thrombolysin is a pharmaceutical composition made by a chemical or biological process.

Metadata:
- Claim Count in Document: 22.0
- Percentile: 97.0
- Lexical Diversity: 1.54412
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12606884', '13030249', '13747307', '15400526', '15439154']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7818299797396477
- 35 USC 102 Novelty (BERT): 0.5233536893744672
- Combined Prediction Score: 0.7559823507031297
- Mean Citation Score: 278.11082400000004
- Max Citation Score: 289.6896700000001
- Similarity Product: 163.31597858686334

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test